Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
WALTHAM, Mass. - Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company with a market capitalization of approximately $42 million, will present late-breaking Phase 2 data for its tumor-activated anti-CTLA-4 therapy vilastobart at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting in November. According to InvestingPro data, the company is currently considered undervalued based on Fair Value estimates.
The presentation will focus on response rates for vilastobart in combination with atezolizumab in patients with microsatellite stable metastatic colorectal cancer and high plasma tumor mutational burden.
The poster presentation, titled "Plasma Tumor Mutational Burden (pTMB) Enriched for Response to Vilastobart in Combination with Atezolizumab in Patients with Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)," will be displayed on Friday, November 7, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland.
Vilastobart is part of Xilio’s pipeline of tumor-activated immunotherapy candidates designed to localize anti-tumor activity within the tumor microenvironment. The company states these therapies aim to improve cancer treatment outcomes while reducing systemic side effects associated with current immunotherapies. InvestingPro data shows Xilio boasts impressive gross profit margins of 86.8% despite not yet being profitable.
The SITC Annual Meeting, taking place November 5-9, 2025, brings together professionals in cancer immunotherapy to share clinical advances and research developments.
According to the press release statement, Xilio Therapeutics is a clinical-stage biotechnology company focused on developing masked immuno-oncology therapies that target activity to tumor sites.
In other recent news, Xilio Therapeutics has received approval to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. This transfer will take effect at the opening of business on Monday, with the company’s shares continuing to trade under the symbol XLO. Additionally, Xilio has initiated the Phase 2 portion of its clinical trial for efarindodekin alfa, a tumor-activated IL-12 therapy for advanced solid tumors. This development has triggered a $17.5 million payment from Gilead Sciences, expected by the fourth quarter of 2025. Furthermore, Leerink Partners has initiated coverage on Xilio Therapeutics with an Outperform rating and a price target of $2.00. The firm expressed optimism about Xilio’s lead clinical program, vilastobart, which has shown efficacy in certain colorectal cancer cases. These recent developments highlight key advancements in Xilio’s clinical programs and financial arrangements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.